Flo Nozoil contains all three natural forms of Vitamin E (alpha, beta and gamma). Flo Nozoil is available in either a metered pump spray or squeeze dropper bottle. In pivotal clinical studies supporting the use of Mozobil, all patients received daily morning doses of 10 μg/kg G-CSF for 4 consecutive days prior to the first dose of plerixafor and on each morning prior to apheresis. Vomiting, abdominal pain, stomach discomfort, dyspepsia, abdominal distention, constipation, flatulence, hypoaesthesia oral, dry mouth Mozobil is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2). Adults: 2-4 drops per nostril 2-3 times daily as required. Children from 4 to 12 years: 1-2 drops per nostril twice daily as required.

The efficacy and safety of Mozobil were evaluated in an open label, multi-center, controlled study in paediatric patients with solid tumors (including neuroblastoma, sarcoma, Ewing sarcoma) or lymphoma who were eligible for autologous hematopoietic stem cell transplantation (DFI12860). Patients with leukemia, persistent high percentage marrow involvement prior to mobilization, or previous stem cell transplantation were excluded. No dose modifications are necessary in elderly patients with normal renal function. Dose adjustment in elderly patients with creatinine clearance ≤ 50 ml/min is recommended (see Renal impairment above). In general, care should be taken in dose selection for elderly patients due to the greater frequency of decreased renal function with advanced age. Authority to prescribe an Authority medicine is granted for specific indications and/or for certain patient circumstances. Authority may be obtained by telephone to Medicare Australia (known as "phone approval") or in writing from an authorised delegate of the Minister for Health. If you are using another nasal product, apply Flo Nozoil at least 20 minutes afterwards. For further information, please refer to your healthcare practitioner. Are there any side effects when using Flo Nozoil? function e(){var e=document.createElement('script');e.type='text/javascript',e.async=true,e.src='//staticw2.yotpo.com/MCN0waWlSaGnmquVBtpvetg2aznN9nNnQb9m8rPf/widget.js';var t=document.getElementsByTagName('script')[0];t.parentNode.insertBefore(e,t)})();

Colds – during and after a cold or flu your nose may become sore due to crusting or excessive nose blowing. The pharmacokinetics of plerixafor have been evaluated in lymphoma and multiple myeloma patients at the clinical dose level of 0.24 mg/kg following pre-treatment with G-CSF (10 μg/kg once daily for 4 consecutive days).

Depending on your preference, you may find one form of Flo Nozoil more suitable than the other. Refer below for specific directions of each. Based on increasing exposure with increasing body weight the dose should not exceed 27 mg/day if the creatinine clearance is lower than 50 ml/min. To obtain the best results from your nasal spray follow the simple instructions given below. If you are unclear about how to use the nasal spray ask your doctor or pharmacist to explain.

Precautions

Nasal CPAP and oxygen therapy - nasal CPAP and oxygen therapy may cause nasal dryness or congestion. Flo Nozoil has been clinically trialled in CPAP therapy and shown to help alleviate nasal dryness and improve the comfort of CPAP treatment. Plerixafor is rapidly absorbed following subcutaneous injection, reaching peak concentrations in approximately 30-60 minutes (t max). Following subcutaneous administration of a 0.24 mg/kg dose to patients after receiving 4-days of G-CSF pre-treatment, the maximal plasma concentration (C max) and systemic exposure (AUC 0-24) of plerixafor were 887 ± 217 ng/ml and 4337 ± 922 ng·hr/ml, respectively.

Thirty patients were treated with 0.24 mg/kg of Mozobil in an open label, multicenter, controlled study (DFI 12860) (see section 5.1). Some drugs may have Authority Required (Streamlined) status which does not require an explicit approval from Medicare, instead the doctor can use the Authority code found in the published Schedule for a given drug/indication. Plerixafor is not metabolised in vitro using human liver microsomes or human primary hepatocytes and does not exhibit inhibitory activity in vitro towards the major drug-metabolising CYP450 enzymes (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4/5). In in vitro studies with human hepatocytes, plerixafor does not induce CYP1A2, CYP2B6, and CYP3A4 enzymes. These findings suggest that plerixafor has a low potential for involvement in P450-dependent drug-drug interactions. Carcinogenicity studies with plerixafor have not been conducted. Plerixafor was not genotoxic in an adequate battery of genotoxicity tests. Immediate hypersensitivity reactions following the use of Rinaspray have been demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, oropharyngeal oedema and anaphylaxis.

Instructions: Start by blowing your nose well. Then remove the plastic cap from the bottle. Pump a couple of times until the nasal oil is delivered in the form of a spray. This is particularly important before the nasal spray is used for the first time or when it has not been used for some time. Nozoil is an oil-based product. Avoid stains on wallpaper, walls and so on by pumping onto a piece of kitchen paper, for example, until the oil starts to come out of the bottle. Administration of Mozobil in conjunction with G-CSF increases circulating leukocytes as well as haematopoietic stem cell populations. White blood cell counts should be monitored during Mozobil therapy. Clinical judgment should be exercised when administering Mozobil to patients with peripheral blood neutrophil counts above 50 x 10 9/L.